{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:15:34Z","timestamp":1792314934631,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11899-016-0304-7","type":"journal-article","created":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T04:55:42Z","timestamp":1456808142000},"page":"86-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase"],"prefix":"10.1007","volume":"11","author":[{"given":"Sudipto","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"304_CR1","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038\u201342.","journal-title":"N Engl J Med"},{"key":"304_CR2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.hoc.2004.03.011","volume":"18","author":"J Cortes","year":"2004","unstructured":"Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:569\u201384.","journal-title":"Hematol Oncol Clin North Am"},{"key":"304_CR3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C","volume":"61","author":"H Kantarjian","year":"1988","unstructured":"Kantarjian H et al. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61:1441\u201346.","journal-title":"Cancer"},{"key":"304_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0037-1963(03)70045-6","volume":"40","author":"J Cortes","year":"2003","unstructured":"Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol. 2003;40:79\u201386.","journal-title":"Semin Hematol"},{"key":"304_CR5","unstructured":"Howlader N et al. (eds). SEER Cancer Statistics Review, 1975\u20132012, National Cancer Institute. Bethesda, MD."},{"issue":"9","key":"304_CR6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","volume":"119","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood. 2012;119(9):1981\u201387.","journal-title":"Blood"},{"issue":"23","key":"304_CR7","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408\u201317.","journal-title":"N Engl J Med"},{"issue":"24","key":"304_CR8","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251\u201359.","journal-title":"N Engl J Med"},{"issue":"24","key":"304_CR9","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260\u201370.","journal-title":"N Engl J Med"},{"key":"304_CR10","doi-asserted-by":"crossref","unstructured":"Radich JP, The biology of CML blast crisis. Hematol Am Soc Hematol Educ Program. 2007:384\u201391.","DOI":"10.1182\/asheducation-2007.1.384"},{"issue":"11","key":"304_CR11","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010\u201322.","journal-title":"Blood"},{"key":"304_CR12","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.2408149","volume":"247","author":"TG Lugo","year":"1990","unstructured":"Lugo TG et al. Tyrosine kinase activity and transformation potency of the BCR-ABL oncogene products. Science. 1990;247:1079\u201382.","journal-title":"Science"},{"issue":"6","key":"304_CR13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306\u201315.","journal-title":"Cancer"},{"key":"304_CR14","volume-title":"WHO classification of tumours of haematopotietic and lymphoid tissues","author":"JWMJ Vardiman","year":"2008","unstructured":"Vardiman JWMJ, Baccarani M, Thiele J. Chronic myelogenous leukemia BCR-ABL1 positive. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopotietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.","edition":"4"},{"issue":"1","key":"304_CR15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","volume":"8378","author":"B Speck","year":"1984","unstructured":"Speck B et al. Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia. Lancet. 1984;8378(1):665\u201368.","journal-title":"Lancet"},{"issue":"6","key":"304_CR16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384. Updated recommendations of the European LeukemiaNet regarding the management of chronic myeloid leukemia, including accelerated and blast phases.","journal-title":"Blood"},{"key":"304_CR17","doi-asserted-by":"crossref","unstructured":"Kantarjian H et al. Survival benefit with imatinib mesylate therapy inpatients with accelerated-phase chronic myelogenous leukemia \u2013 comparison with historic experience. Cancer. 2005;103(10):2099\u2013108.","DOI":"10.1002\/cncr.21032"},{"key":"304_CR18","doi-asserted-by":"crossref","unstructured":"Jiang Q et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood. 2011;117(11):3032\u201340.","DOI":"10.1182\/blood-2010-09-308510"},{"key":"304_CR19","doi-asserted-by":"crossref","unstructured":"Hoffmann VS et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27(10):2016\u201322.","DOI":"10.1038\/leu.2013.171"},{"key":"304_CR20","doi-asserted-by":"crossref","unstructured":"Furtado VF et al. Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase. Rev Bras Hematol Hemoter. 2015;37(5):341-7.","DOI":"10.1016\/j.bjhh.2015.07.004"},{"key":"304_CR21","unstructured":"Kantarjian HM et al.\u00a0Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.\u00a0Clin Cancer Res. 2002;8(7):2167\u201376."},{"issue":"6","key":"304_CR22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99(6):1928\u201337.","journal-title":"Blood"},{"issue":"10","key":"304_CR23","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","volume":"109","author":"F Guilhot","year":"2007","unstructured":"Guilhot F et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109(10):4143\u201350.","journal-title":"Blood"},{"key":"304_CR24","doi-asserted-by":"crossref","unstructured":"Kantarjian H et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113(25):6322\u20139. 405.","DOI":"10.1182\/blood-2008-11-186817"},{"issue":"21","key":"304_CR25","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","volume":"27","author":"JF Apperley","year":"2009","unstructured":"Apperley JF et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol. 2009;27(21):3472\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"304_CR26","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.323","volume":"26","author":"PD Coutre le","year":"2012","unstructured":"le Coutre PD et al. Nilotinib in patients with Ph\u2009+\u2009chronic myeloid leukemia in accelerated phase following imatinib resistance or in- tolerance: 24-month follow-up results. Leukemia. 2012;26(6):1189\u201394.","journal-title":"Leukemia"},{"issue":"24","key":"304_CR27","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"304_CR28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3109\/10428194.2011.627480","volume":"53","author":"FE Nicolini","year":"2012","unstructured":"Nicolini FE et al. Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis. Leuk Lymphoma. 2012;53(5):907\u201314.","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"304_CR29","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/ajh.24034","volume":"90","author":"C Gambacorti-Passerini","year":"2015","unstructured":"Gambacorti-Passerini C et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance\/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90(9):755\u201368. This study established the long-term (>4 years of follow-up) efficacy and safety of bosutinib in accelerated phase CML patients refractory or resistant to prior treatment with imatinib, nilotinib, and dasatinib.","journal-title":"Am J Hematol"},{"issue":"19","key":"304_CR30","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396. This is a landmark study that demonstrated the efficacy of ponatinib as a salvage strategy in CML patients across all disease phases including accelerated phase CML with unmutated or mutated BCR-ABL who were refractory to nilotinib and dasatinib. Additionally, this study established ponatinib as the only TKI with activity in CML patients harboring T315I mutation.","journal-title":"N Engl J Med"},{"key":"304_CR31","first-page":"509","volume":"12","author":"A Gratwohl","year":"1993","unstructured":"Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant. 1993;12:509\u201316.","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl","key":"304_CR32","first-page":"115","volume":"6","author":"P McGlave","year":"1992","unstructured":"McGlave P. Therapy of chronic myelogenous leukemia with related or unrelated donor bone marrow transplantation. Leukemia (Baltimore). 1992;6(Suppl):115\u201317.","journal-title":"Leukemia (Baltimore)"},{"key":"304_CR33","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1182\/blood.V84.12.4368.bloodjournal84124368","volume":"84","author":"RA Clift","year":"1994","unstructured":"Clift RA et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood. 1994;84:4368\u201373.","journal-title":"Blood"},{"key":"304_CR34","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","volume":"86","author":"S Sacchi","year":"1999","unstructured":"Sacchi S et al. Chronic myelogenous leukemia in nonlymphoid blastic phase. Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632\u201341.","journal-title":"Cancer"},{"key":"304_CR35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1200\/JCO.1992.10.3.398","volume":"10","author":"H Kantarjian","year":"1992","unstructured":"Kantarjian H et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine and granulocyte macrophage colony stimulating factor. J Clin Oncol. 1992;10:398\u2013405.","journal-title":"J Clin Oncol"},{"key":"304_CR36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.1992.10.5.772","volume":"10","author":"H Kantarjian","year":"1992","unstructured":"Kantarjian H et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-\u03b1 and low-dose cytarabine. J Clin Oncol. 1992;10:772\u201378.","journal-title":"J Clin Oncol"},{"key":"304_CR37","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2000.18.20.3513","volume":"18","author":"H Kantarjian","year":"2000","unstructured":"Kantarjian H et al. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia. J Clin Oncol. 2000;18:3513\u201321.","journal-title":"J Clin Oncol"},{"key":"304_CR38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.2001.19.3.762","volume":"19","author":"FJ Giles","year":"2001","unstructured":"Giles FJ et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol. 2001;19:762\u201371.","journal-title":"J Clin Oncol"},{"key":"304_CR39","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","volume":"94","author":"RT Silver","year":"2009","unstructured":"Silver RT et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukaemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94:743\u201344.","journal-title":"Haematologica"},{"issue":"7","key":"304_CR40","first-page":"2167","volume":"8","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002;8(7):2167\u201376.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"304_CR41","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","volume":"26","author":"D Rea","year":"2012","unstructured":"Rea D et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia. 2012;26(10):2254\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"304_CR42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","volume":"94","author":"F Palandri","year":"2009","unstructured":"Palandri F et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica. 2009;94(2):205\u201312.","journal-title":"Haematologica"},{"key":"304_CR43","doi-asserted-by":"crossref","unstructured":"Silver RT et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood. 2004;104:Abstract 23.","DOI":"10.1182\/blood.V104.11.23.23"},{"key":"304_CR44","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A et al. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18:1321\u201331.","journal-title":"Leukemia"},{"issue":"2","key":"304_CR45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","volume":"14","author":"M Ohanian","year":"2014","unstructured":"Ohanian M et al. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014;14(2):155\u201362 e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"304_CR46","doi-asserted-by":"crossref","unstructured":"Khoury HJ, et al. Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors. Leuk Lymphoma. 2014.","DOI":"10.3109\/10428194.2014.889826"},{"issue":"3","key":"304_CR47","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.hoc.2004.03.013","volume":"18","author":"JP Radich","year":"2004","unstructured":"Radich JP et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am. 2004;18(3):685\u2013702.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"304_CR48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","volume":"137","author":"SA Giralt","year":"2007","unstructured":"Giralt SA et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137(5):461\u20137.","journal-title":"Br J Haematol"},{"issue":"9","key":"304_CR49","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","volume":"7","author":"S O\u2019Brien","year":"2009","unstructured":"O\u2019Brien S et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009;7(9):984\u20131023.","journal-title":"J Natl Compr Canc Netw"},{"issue":"Suppl 2","key":"304_CR50","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","volume":"9","author":"S O\u2019Brien","year":"2011","unstructured":"O\u2019Brien S, Berman E, Moore JO, et al. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw. 2011;9 Suppl 2:S1\u201325.","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"304_CR51","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","volume":"117","author":"E Jabbour","year":"2011","unstructured":"Jabbour E et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011;117(13):3641\u20137.","journal-title":"Blood"},{"issue":"8","key":"304_CR52","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","volume":"112","author":"SJ Lee","year":"2008","unstructured":"Lee SJ et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008;112(8):3500\u20137.","journal-title":"Blood"},{"issue":"6","key":"304_CR53","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","volume":"47","author":"HJ Khoury","year":"2012","unstructured":"Khoury HJ et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012;47(6):810\u20136.","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"304_CR54","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","volume":"109","author":"VG Oehler","year":"2007","unstructured":"Oehler VG et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood. 2007;109(4):1782\u20139.","journal-title":"Blood"},{"issue":"2","key":"304_CR55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.leukres.2009.04.036","volume":"34","author":"M Breccia","year":"2010","unstructured":"Breccia M et al. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res. 2010;34(2):143\u20137.","journal-title":"Leuk Res"},{"issue":"2","key":"304_CR56","first-page":"47","volume":"2","author":"AL Latif","year":"2013","unstructured":"Latif AL et al. Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: a single centre\u2019s experience. Leuk Res Rep. 2013;2(2):47\u201350.","journal-title":"Leuk Res Rep"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0304-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-016-0304-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-016-0304-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T07:54:40Z","timestamp":1600242880000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-016-0304-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1007\/s11899-016-0304-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}